NFTG(US:NFTG)2025-11-13 21:16Revenue Generation - For the three months ended September 30, 2025, the company generated revenues of $498,271, primarily from RNK Health, which provided non-clinical services amounting to $441,228[133]. - During the nine months ended September 30, 2025, total revenues reached $692,974, with RNK Health contributing $634,178 from non-clinical services[134]. Operating Expenses - Operating expenses for the three months ended September 30, 2025, were $1,813,026, reflecting a 99.5% increase from $908,573 in the same period of 2024[135]. - Total general and administrative expenses for the nine months ended September 30, 2025, amounted to $3,644,088, up from $2,122,607 in 2024, marking a significant increase[139]. - Other general and administrative expenses for the three months ended September 30, 2025, rose to $254,618, an increase of $152,618 or 149.6% compared to the same period in 2024[147]. - Compensation and related benefits increased by 39.5% to $962,098 for the nine months ended September 30, 2025, primarily due to executive bonuses and stock-based compensation[141]. Research and Development - Research and development fees increased by 8.5% to $274,021 for the three months ended September 30, 2025, compared to $252,657 in 2024[136]. - The company plans to pursue research and development of its products, which will require additional capital from third-party sources[163]. Marketing and Advertising - Advertising and marketing expenses surged by 638.9% to $903,258 for the three months ended September 30, 2025, compared to $122,247 in 2024[144]. - For the three months ended September 30, 2025, advertising and marketing fees increased by $761,670, contributing to the growth in RNK Health services[145]. Losses and Financial Position - The loss from operations for the three months ended September 30, 2025, was $1,314,755, an increase of $408,886 or 45.1% from the previous year[149]. - The net loss attributable to common shareholders for the three months ended September 30, 2025, was $1,001,474, or $0.14 per share, reflecting an increase of $137,064 or 15.9% year-over-year[152]. - For the nine months ended September 30, 2025, net cash used in operations was $3,120,632, primarily due to a net loss of $3,197,507[157]. - The company expects to continue generating operating losses in the foreseeable future due to corporate overhead and research and development costs[156]. Cash and Investments - As of September 30, 2025, the company had a cash balance of $914,183 and short-term investments totaling $12,058,377, with working capital of $12,968,843[154]. - The company reported net cash used in investing activities of $10,363,284 for the nine months ended September 30, 2025, mainly from the purchase of short-term investments[159]. - The company did not have any cash flows from financing activities for the nine months ended September 30, 2025[161]. New Initiatives - The company launched four proprietary games by September 30, 2025, enhancing user engagement through AI-driven personalization and NFT features[124]. - Gaxos Health, a new initiative, aims to provide AI-powered health optimization solutions, with the product launched in Q3 2024[126][127]. - RNK Health LLC was formed to market health-related products, with the company holding a 70% membership interest[128].